David J. Newman
Impact in
- Pharmacology top 0.02%
- Microbial Natural Products and Biosynthesis
- Drug Discovery top 0.2%
Papers in
- Pharmacology 60
- Microbial Natural Products and Biosynthesis 60
-
- Marine Sponges and Natural Products 20
- Co-authors
- Gordon M. L. Cragg (73 shared papers)Kenneth M. Snader (5 shared papers)Paul G. Grothaus (13 shared papers)Charles Sutton Zender (2 shared papers)Huisheng Bian (1 shared paper)Padhraic Smyth (11 shared papers)Timothy J. Baldwin (8 shared papers)Jey Han Lau (6 shared papers)
- Journals
- Journal of Natural Products (34 papers)Proceedings of the American Mathematical Society (16 papers)Clinical Chemistry (12 papers)Annals of Clinical Biochemistry International Journal of Laboratory Medicine (10 papers)Natural Product Reports (7 papers)
- Partner nations
- United StatesUnited KingdomAustralia
In The Last Decade
David J. Newman
372 papers receiving 43.6k citations
David J. Newman's Hit Papers
Peers
Comparison fields: 5 of 203
- Pharmacology 5.5k
- Drug Discovery 29
- Biotechnology 1.3k
- Computational Theory and Mathematics 1.7k
- Complementary and alternative medicine 797
Countries citing papers authored by David J. Newman
This map shows the geographic impact of David J. Newman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. Newman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. Newman more than expected).
Fields of papers citing papers by David J. Newman
This network shows the impact of papers produced by David J. Newman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. Newman. The network helps show where David J. Newman may publish in the future.
Co-authors
The 25 scholars most cited alongside David J. Newman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 391 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019 Hit paper breakdown → | 2020 | 5131 |
| 2 | Natural Products as Sources of New Drugs from 1981 to 2014 Hit paper breakdown → | 2016 | 4882 |
| 3 | Natural Products as Sources of New Drugs over the Last 25 Years Hit paper breakdown → | 2007 | 4649 |
| 4 | Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010 Hit paper breakdown → | 2012 | 3997 |
| 5 | Natural Products as Sources of New Drugs over the Period 1981−2002 Hit paper breakdown → | 2003 | 2492 |
| 6 | Natural products: A continuing source of novel drug leads Hit paper breakdown → | 2013 | 2371 |
| 7 | Plants as a source of anti-cancer agents Hit paper breakdown → | 2005 | 1694 |
| 8 | Natural Products in Drug Discovery and Development Hit paper breakdown → | 1997 | 1252 |
| 9 | Impact of Natural Products on Developing New Anti-Cancer Agents Hit paper breakdown → | 2009 | 1132 |
| 10 | The influence of natural products upon drug discovery (Antiquity to late 1999) Hit paper breakdown → | 2000 | 1063 |
| 11 | Mineral Dust Entrainment and Deposition (DEAD) model: Description and 1990s dust climatology Hit paper breakdown → | 2003 | 990 |
| 12 | UCI Repository of Machine Learning Database Hit paper breakdown → | 1998 | 699 |
| 13 | Marine Natural Products and Related Compounds in Clinical and Advanced Preclinical Trials Hit paper breakdown → | 2004 | 636 |
| 14 | Natural Products as Leads to Potential Drugs: An Old Process or the New Hope for Drug Discovery? Hit paper breakdown → | 2008 | 606 |
| 15 | The odyssey of marine pharmaceuticals: a current pipeline perspective Hit paper breakdown → | 2010 | 551 |
| 16 | Automatic evaluation of topic coherence Hit paper breakdown → | 2010 | 531 |
| 17 | Fast collapsed gibbs sampling for latent dirichlet allocation Hit paper breakdown → | 2008 | 418 |
| 18 | 2001 | 357 | |
| 19 | 2005 | 290 | |
| 20 | Distributed Algorithms for Topic Models | 2009 | 276 |
About David J. Newman
David J. Newman is a scholar working on Pharmacology, Biotechnology, Nephrology, Applied Mathematics and Algebra and Number Theory, having authored 391 papers that have together received 46.8k indexed citations. Recurring topics across this work include Microbial Natural Products and Biosynthesis (60 papers), Marine Sponges and Natural Products (20 papers), Topic Modeling (15 papers), Clinical Laboratory Practices and Quality Control (9 papers), Chronic Kidney Disease and Diabetes (9 papers), Bioactive Natural Diterpenoids Research (6 papers), Analytic Number Theory Research (6 papers) and Advanced Biosensing Techniques and Applications (6 papers). The work is most often cited by research in Pharmacology (5.5k citations), Drug Discovery (29 citations), Biotechnology (1.3k citations), Computational Theory and Mathematics (1.7k citations) and Complementary and alternative medicine (797 citations). David J. Newman has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Gordon M. L. Cragg, Kenneth M. Snader, Paul G. Grothaus, Charles Sutton Zender, Huisheng Bian, Padhraic Smyth, Timothy J. Baldwin, Jey Han Lau, Christopher P. Price and Max Welling. Their work appears in journals such as Journal of Natural Products, Proceedings of the American Mathematical Society, Clinical Chemistry, Annals of Clinical Biochemistry International Journal of Laboratory Medicine and Natural Product Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.